

## **DIVISION OF CARDIOLOGY- SUMMARY OF WEEKLY ROUNDS**

Monday, November 18 - Friday, November 22, 2019

### **Monday, November 18:**

8:00-9:00	Aud B UH, B2-116 VH & B2-075 St. Joseph's  <i>OTN Event #: 135171686</i>	<b>Cardiovascular Grand Rounds</b> Presenter: <b>R. Bagur</b> Title of Presentation: <b>Antithrombotic Therapy in Patients Undergoing Coronary Artery Bypass Graft Surgery</b> <b>Learning Objectives:</b> 1. To recognize common barriers associated with the management of antiplatelet therapy in patients undergoing CABG surgery. 2. To evaluate the most recent data on antithrombotic therapy for the prevention of saphenous vein graft failure (SVGf) after CABG surgery. 3. To evaluate the comparative efficacy and harms of different antithrombotic drugs using a multiple treatment comparison analysis.
12:00-1:30	B6-115 UH  <i>OTN Event #: 102030427</i>	<b>Adult Congenital Cardiac Surgery Rounds</b> <i>Videoconference from Toronto</i> <b>Case-based presentation and discussion</b> <b>Learning Objectives:</b> 1. To describe long-term complications and outcomes in adults with congenital disease. 2. To formulate a rational approach to the diagnosis and treatment of long-term complications in adults with congenital heart disease. 3. To recognize different diagnostic and therapeutic approaches in the treatment of adults with congenital heart disease. 4. To understand the importance of a systematic, multidisciplinary team approach to provide excellent care for adults with congenital heart disease.

### **Tuesday, November 19:**

7:00-8:00	B6-115 UH  <i>OTN Event #: 135175917</i>	<b>Complex Revascularization Rounds</b> Presenters: <b>CV Surgeons &amp; Interventionalists</b> Faculty Supervisors: <b>D. Nagpal/P. Garg</b> <b>Case-based presentation and discussion</b> <b>Learning Objectives:</b> 1. To develop a systematic approach to interpretation of coronary angiograms. 2. To discuss interesting case examples and their management. 3. To apply an evidence-based approach to complex revascularization cases in order to improve outcomes.
8:00-9:00	B6-115 UH & B2-074 St. Joseph's  <i>OTN Event #: 135179297</i>	<b>Heart Failure Rounds</b> Presenters: <b>Attendings &amp; NPs</b> Faculty Supervisors: <b>S. Smith, R. McKelvie &amp; S. MacGregor</b> <b>Learning Objectives:</b> 1. To develop a systematic approach for management of patients with advanced heart failure despite usual care. 2. To discuss challenging cases and develop management plans. 3. To apply patient centered, evidence-based approach to advanced heart failure care in order to improve outcomes, decrease hospitalization and ensure that patients' goals are addressed to the best of our ability.
2:00-5:00	B6-128 UH	<b>ACADEMIC HALF DAY/DIDACTIC EDUCATION SESSIONS</b>
2:00-3:00		<b>Thrombolytic agents</b> Presenter: <b>T. Kafil</b> Faculty Supervisor: <b>A. Mathew</b> <b>Learning Objectives:</b> TBA
3:00-4:00		<b>Definitions &amp; pathogenesis of acute coronary syndromes and atherosclerosis (BSS)</b> Presenter: <b>G. Pickering</b> <b>Learning Objectives:</b> TBA
4:00-5:00		<b>ACHD: Ebstein's malformation, including ECHO features</b> Presenter: <b>P. Antiperovitch</b> Faculty Supervisor: <b>B. Dias</b> <b>Learning Objectives:</b> 1. Define diagnostic features for Ebstein's malformation. 2. List key historical and physical exam features of Ebstein's malformation. 3. Review indications for repair.
6:00	<i>Crossings Pub and Eatery, 1269 Hyde Park Road, London</i>  <i>Sponsor: AstraZeneca</i>	<b>Heart Failure Journal Club</b> <i>Attendance open to members of the Heart Failure Service and Cardiology Residents. RSVP to Cathy Ward-Rollinson (Ext. 33428 or email cathy.wardrollinson@lhsc.on.ca)</i> Topic: <b>SGLT2 Inhibitors in HF</b> <b>Papers for Presentation:</b> 1. Dan Durocher: <b>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</b> B. Zinman, MD, et al. N Engl J Med 2015;373:2117-28 2. Brennan Ballantyne: <b>Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction</b> J.J.V. McMurray, et al. DOI: 10.1056/NEJMoa1911303 <b>Learning Objectives:</b> 1. To explore the evidence for SGLT-2 inhibition in heart failure. 2. To understand mechanisms for benefit of SGLT-2 inhibitors in heart failure. 3. To discuss clinical implications of recent trials in the treatment of heart failure. 4. To contrast potential differences, side effects and properties of different SGLT-2 inhibitors.

Wednesday, November 20:

8:00-9:00	B6-115 UH	<b>EP Rounds: Tracing Rounds</b> Presenters: <b>Attendings &amp; Fellows</b> <b>Learning Objectives:</b> 1. To develop a systematic approach to EP tracings. 2. To discuss interesting case examples. 3. To review electrophysiology principles and concepts.
6:00	<i>583 Eclipse Walk, London</i>  <i>Sponsor: Medtronic</i>	<b>Electrophysiology Journal Club</b> <i>Attendance open to Electrophysiologists and EP Fellows, Cardiology Residents and EP Research Staff. RSVP to Charlene Grass (Ext. 33830 or email charlene.grass@lhsc.on.ca)</i> Topic: <b>Andersen Tawil Syndrome</b> <b>Papers to be reviewed:</b> 1. Will Chan: <b>Electrocardiographic Features in Andersen Tawil Syndrome Patients With KCNJ2 Mutations Characteristic T-U-Wave Patterns Predict the KCNJ2 Genotype</b> Li Zhang et al. Circulation. 2015;111:2720-2726 2. Juliana Kanawati: <b>Phenotype Variability in Patients Carrying KCNJ2 Mutations</b> Hiromi Kimura et al. Circ Cardiovasc Genet. 2012;5:344-353 3. Matthew Rowe: <b>Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation</b> Eric Delannoy et al. Eurpace 2013 15, 1805-1811 4. Habib Khan: <b>Efficacy and safety to flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations</b> Kohi Miyamoto et al. Heart Rhythm 2015;12:596-603 <b>Learning Objectives:</b> 1. To systematically appraise and assimilate scientific evidence from journal articles and how it can be applied to clinical practice and improvement in patient care. 2. To stay up-to-date with advances in biomedical and clinical evidence and to facilitate self-learning and professional development. 3. To provide a forum for discussion and peer-review between health care professionals on current best practice that is evidence based.

Thursday, November 21:

7:00-8:00	B6-115 UH & B2-122 VH  <i>OTN Event #: 147957797</i>	<b>Cardiac Cath/Interventional Rounds</b> Presenter: <b>W. Sumaya</b> Faculty Supervisor: <b>M. Ward</b> Title of Presentation: <b>Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy</b> <b>Learning Objectives:</b> 1. How to approach a patient with HCM. 2. Evidence and indications for alcohol septal ablation.
8:00-9:00	B6-128 UH	<b>Graphics Rounds: HF</b> Presenter: <b>L. Goldraich</b>
12:00-1:00	B6-115 UH, B2-122 VH, B3-655 St. Joseph's  <i>OTN Event #: 135202462</i>	<b>Echocardiography Rounds</b> Presenters: <b>Fellows &amp; Attendings</b> <b>Learning Objectives:</b> 1. To discuss technical aspects related to the acquisition of cardiac ultrasound. 2. To discuss the anatomical and physiological principles underlying echocardiography images. 3. To understand how echocardiography may assist in the management of patients with known or suspected cardiac disease.

Friday, November 22:

8:00-9:00	B6-115 UH  <i>OTN Event #: 135207069</i>	<b>EP Rounds: Device Rounds</b> Presenters: <b>Attendings &amp; Fellows</b> <b>Learning Objectives:</b> 1. To develop a systematic approach to device tracings. 2. To discuss interesting case examples. 3. To review programming features and troubleshooting.
12:00-1:00	B6-128 UH	<b>Transplant Rounds</b> Presenters: <b>Attendings &amp; Fellows</b> <b>Learning Objectives:</b> 1. To review the multidisciplinary issues surrounding transplantation and mechanical circulatory support. 2. To understand hemodynamics of heart failure patients. 3. To discuss the psychosocial issues surrounding transplantation and mechanical circulatory support.

Some of these educational activities/rounds are an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, approved by the Division of Cardiology Education Committee - Western University.

*Supported by unrestricted grants-in-aid provided by:*  
*Amgen Canada Inc. (Repatha)*  
*AstraZeneca Canada Inc. (Brilinta (Ticagrelor))*  
*Bayer Inc. (XARELTO® rivaroxaban tablet)*  
*Bristol-Myers Squibb Canada & Pfizer Canada Inc. (Eliquis (apixaban))*  
*Medtronic of Canada Inc.*  
*Novartis Pharmaceuticals Canada Inc. (Entresto)*  
*Sanofi (Praluent)*  
*Servier Canada Inc. (Lixiana, Lancora)*